ケンタッキー州におけるクローン病の臨床試験
ケンタッキー州内の拠点で、クローン病に関する12件の研究が参加者を募集しています。
ケンタッキー州内の都市
公式研究テキスト（英語）
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Louisville Hospital ( Site 5120), Louisville
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/10/02更新 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Health Partners /ID# 284144, Louisville
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/02更新 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Tri-State Gastroenterology Associates, Crestview Hills
被験者募集中第4相
18歳〜80歳 · 全性別 · 2026/09/30更新 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Kentucky Chandler Medical Center /ID# 265564, Lexington
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Tri-State Gastroenterology Assoc, Crestview Hills
- University of Louisville - MedCenter One, Louisville
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- University Of Louisville, Louisville
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Health Partners, Louisville
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of Kentucky/Markey Cancer Center, Lexington
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- University of Kentucky Hospital/UK Albert B. Chandler Hospital-Site Number: 8400058, Lexington
被験者募集中第3相
16歳〜80歳 · 全性別 · 2026/09/23更新 · NCT07184931A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Louisville, Louisville
被験者募集中第4相
18歳〜70歳 · 全性別 · 2026/09/09更新 · NCT06045754A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- Tri-State Gastroenterology Assoc, Crestview Hills
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07577843Treatment of Moderate to Severe Refractory Crohn's Disease
- University of Louisville, Louisville
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2025/12/10更新 · NCT06721962ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。